Home
    • Plans Blog Contact
    Sophia Genetics SA logo

    Sophia Genetics SA

    SOPH
    Last price US$5.72
    Market cap US$391.8m
    12M price change 61.13%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    National Research CorpNRC Industry peer HealthStream IncHSTM Industry peer VEEVA SYSTEMS INCVEEV Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Sophia Genetics SA Overview

    Industry: Health Information Services

    Sector: Healthcare

    SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharma customers worldwide. The company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland. SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and rela Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Sophia Genetics SA into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 05, 2026

    Quarterly result summary

    Revenue was $21.7M (+22% YoY). Net loss was -$19.3M. Adjusted EBITDA was $9.2M.

    Revenue $21.7M +22% YoY
    Net loss -$19.3M reported
    Adjusted EBITDA $9.2M reported

    What changed

    • Revenue +22% YoY to $21.7M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing EX-99.2 Jun 22, 2026 SEC filing EX-99.3 Jun 22, 2026 SEC filing EX-99.1 Jun 22, 2026 SEC filing 6-K Jun 04, 2026 SEC filing 6-K May 05, 2026 Earnings release Earnings release May 05, 2026 SEC filing 20-F Mar 03, 2026 Earnings release Earnings release Mar 03, 2026 SEC filing 6-K Mar 03, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Sophia Genetics SA earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Return on Equity

    Score 1.96/5
    Sophia Genetics SA exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Sophia Genet... SOPH US$391.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Sophia Genetics SA olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Sophia Genet... SOPH US$391.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Leverage

    Score 3.08/5
    Sophia Genetics SA attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Sophia Genet... SOPH US$391.8m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Sophia Genetics SA logo

    Sophia Genetics SA

    US$5.72

    US$391.8m

    -2.56%

    61.13%